December 21, 2022
From a billion-dollar deal in Delaware to a hard-fought battle over a bribery scandal involving Ohio's legislature, securities litigators secured big settlements this year that sprang from both class actions and derivative suits, with a high number of resolutions occurring in Delaware Chancery Court.
January 27, 2022
A Connecticut federal judge granted preliminary approval to a $420 million deal resolving an investor class action accusing Teva Pharmaceuticals of orchestrating an industrywide price-fixing scheme, holding that the agreement is reasonable and there are no obvious red flags.
January 18, 2022
Teva Pharmaceutical Industries Ltd. has agreed to pay $420 million to resolve an investor class action accusing the pharmaceutical giant of being at the center of an industrywide price-fixing scheme.
March 09, 2021
A Connecticut federal court on Tuesday certified a class of Teva Pharmaceutical investors accusing the company of attributing its success to good business decisions when much of the good fortune was instead due to its participation in an allegedly sprawling generic drug price-fixing conspiracy.
October 21, 2020
A Connecticut federal judge said the U.S. Department of Justice can get involved in a price-fixing case against Teva Pharmaceuticals, but only so antitrust enforcers can explain how the litigation could impact their own probe of the generic-drug giant.
October 01, 2020
Teva Pharmaceuticals urged a Connecticut federal judge Wednesday not to allow shareholders to embark on a "radical fishing expedition" through a slew of company text messages, arguing that the bid for data will only draw the securities fraud class action in the wrong direction.
September 17, 2020
The U.S government has urged a Connecticut federal judge to let it intervene in a private price-fixing case against Teva Pharmaceuticals, saying the case may bring to light information that could be useful in a federal probe of the generic-drug giant.
July 09, 2020
Teva Pharmaceutical Industries Ltd. has urged a Connecticut federal court to toss securities fraud claims that it operated a price-fixing scheme and lied about profit growth, arguing that the allegations were brought too late.
June 22, 2020
Shareholders accusing Teva Pharmaceutical Industries Ltd. of operating a price-fixing scheme and lying about profit growth have asked a Connecticut federal judge to certify their proposed class, arguing that they easily meet all of the federal requirements.
March 11, 2020
A Connecticut federal judge streamlined widespread litigation accusing Teva Pharmaceutical Industries Ltd. of operating a price-fixing scheme and lying about profit growth by consolidating 21 similar suits against the drugmaker Tuesday.